FOSAPREPITANT DIMEGLUMINE

Peak

fosaprepitant

NDAINTRAVENOUSPOWDER
Approved
Sep 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16

Mechanism of Action

accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…

Clinical Trials (5)

NCT04054193Phase 4Completed

Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)

Started Sep 2019
103 enrolled
Chemotherapy-induced Nausea and Vomiting
NCT03578081Phase 3Completed

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Started Nov 2018
690 enrolled
Malignant Neoplasm
NCT02519842Phase 3Terminated

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Started Sep 2015
75 enrolled
Chemotherapy-induced Nausea and Vomiting
NCT02407600Phase 2Unknown

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy

Started Apr 2015
150 enrolled
Non-small Cell Lung CancerVomitingNausea+1 more
NCT01874119Phase 2Terminated

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Started Sep 2013
13 enrolled
Chemotherapy-induced Nausea and Vomiting